Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 901–1,000 of 1,000

Circulating naïve and effector memory T cells correlate with prognosis in head and neck squamous cell carcinoma
Takahashi, H., Sakakura, K., Ida, S., Kawabata‐Iwakawa, R., Matsuyama, T., Tada, H., Mito, I., & Chikamatsu, K. (2021) · Cancer Science · doi:10.1111/cas.15195 · Cited by 25
Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors
Jing, T., Zhang, Z., Kang, Z., Mo, J., Yue, X., Lin, Z., Fu, X., Liu, C. X., Ma, H., Zhang, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00205 · Cited by 30
Personalizing chemotherapy dosing using pharmacological methods
Patel, J. N., & Papachristos, A. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2849-x · Cited by 25
“The past decade of cancer research has seen many significant advances from the dozens of FDA-approved targeted therapies to the hundreds in clinical development [1], in addition to the advancements in immunotherapeutics [2], capitalizing on the host immune system to target tumor killing.”
Background
Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia‐associated antigens
Schneider, V., Zhang, L., Rojewski, M., Fekete, N., Schrezenmeier, H., Erle, A., Bullinger, L., Hofmann, S., Götz, M., Döhner, K., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29583 · Cited by 26
Reconceiving autoimmunity: An overview
Tauber, A. I. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.05.029 · Cited by 27
“Of particular interest, given the renewed excitement about immune therapies for cancer (Couzin-Frankel, 2013), is the largely undefined role of exosomes in modulating the immune response to tumors (Zhang and Grizzle, 2011; Clayton and Mason, 2009; Bobrie and Théry, 2013).”
Background
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Tsai, K. K., & DAUD, A. I. (2015) · Drugs · doi:10.1007/s40265-015-0376-z · Cited by 24
Paving the Road for Modern Particle Therapy – What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?
Specht, H. M., Neff, T., Reuschel, W., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00262 · Cited by 25
“In 2013, immunotherapy was elected as the breakthrough of the year (42).”
Background
Modified breast cancer model for preclinical immunotherapy studies
Katsuta, E., DeMasi, S. C., Terracina, K. P., Spiegel, S., Phan, G. Q., Bear, H. D., & Takabe, K. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.06.003 · Cited by 25
“The early success of immune checkpoint inhibition, such as targeted therapy against cytotoxic Tlymphocyte-associated protein 4 (CTLA-4), along with programmed death-1 (PD-1) (2, 3) and the PD-1 ligand, PD-L1 (4), has drawn much attention (5).”
Background
PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells
Kumar, R., Yu, F. H. Z., Zhen, Y.-H., Li, B., Wang, J., Yang, Y., Ge, H., Hu, P., & Jin, X. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s130131 · Cited by 25
Combining immunotherapy with radiation therapy in thoracic oncology
Badiyan, S. N., Roach, M. C., Chuong, M. D., Rice, S. R., Onyeuku, N. E., Remick, J. S., Chilukuri, S. C., Glass, E., Mohindra, P., & Simone, C. B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.73 · Cited by 25
“In fact, the influence of immunotherapy has been so profound that Science magazine named immunotherapy as the “Breakthrough of the Year” in 2013 (5), and it is now considered to be the fourth pillar of cancer care (6).”
Background
Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma
Vecchio, C. D., Calistri, A., Parolin, C., & Mucignat‐Caretta, C. (2019) · Cancers · doi:10.3390/cancers11030417 · Cited by 25
Recent development in biodegradable nanovehicle delivery system-assisted immunotherapy
Wen, Z., Liu, F., Chen, Q., Xu, Y., Li, H., & Sun, S. (2019) · Biomaterials Science · doi:10.1039/c9bm00961b · Cited by 25
Computational modeling of therapy on pancreatic cancer in its early stages
Chen, J., Weihs, D., & Vermolen, F. J. (2019) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-019-01219-0 · Cited by 25
“Other mathematical models on cancer therapy can be found in Couzin-Frankel (2013) and Namazi et al.”
Method
Nonsurgical management of resectable oral cavity cancer in the wake of COVID-19: A rapid review and meta-analysis
Forner, D. W. A., Noel, C. W., Wu, V., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104849 · Cited by 25
Natural killer cell–mediated anticancer effects of an arabinogalactan derived from rice hull in CT26 colon cancer–bearing mice
Yang, L.-C., Lai, C.-Y., Hsieh, C., & Lin, W. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.200 · Cited by 24
Preparation of Immunotherapy Liposomal-Loaded Thermal-Responsive Hydrogel Carrier in the Local Treatment of Breast Cancer
Tsai, H., Chou, H., Chuang, S., et al. (2019) · Polymers · doi:10.3390/polym11101592 · Cited by 24
“In addition, macrophages can be activated by IMQ and become M1 macrophages [2].”
Background
Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy
Qian, C., Yang, L.-J., & Cui, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00960 · Cited by 24
“Keywords: nanotechnology, dendritic cell, cancer, immunotherapy, antigen delivery, cross-presentation INTRODUCTION Cancer therapies have been evolving with advances in oncology (Couzin-Frankel, 2013).”
Background
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Zeng, G., Jin, L., Ying, Q., Chen, H., Thembinkosi, M. C., Yang, C., Zhao, J., Ji, H., Lin, S., Peng, R., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s265828 · Cited by 26
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 24
Nanotechnology synergized immunoengineering for cancer
Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 27
Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models
Pieper, A. A., Zangl, L. M., Speigelman, D. V., Feils, A. S., Hoefges, A., Jagodinsky, J. C., Felder, M. A. R., Tsarovsky, N. W., Arthur, I. S., Brown, R. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.763888 · Cited by 23
Exosome Transportation-Mediated Immunosuppression Relief Via Cascade Amplification for Enhanced Apoptotic Body Vaccination
Zhao, G., Liu, H., Wang, Z., Yang, H., Zhao, H., Zhang, Y., Ge, K., Wang, X., Luo, L., Zhou, X., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.09.014 · Cited by 25
Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response
Vladimirov, N., & Perlman, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043151 · Cited by 25
Lymph node targeting for immunotherapy
Wang, Y., & Wang, H. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100395 · Cited by 25
Deep Tumor Penetration of CRISPR-Cas System for Photothermal-Sensitized Immunotherapy via Probiotics
Luo, W., Zhang, Z., Zhou, D., Jiang, Y., Yang, J., He, B., Yu, H., & Song, Y. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c02061 · Cited by 26
Niclosamide improves cancer immunotherapy by modulating RNA-binding protein HuR-mediated PD-L1 signaling
Zhang, Q., Yang, Z., Hao, X., Dandreo, L. J., He, L., Zhang, Y., Wang, F., Wu, X., & Xu, L. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01137-w · Cited by 24
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study
Mletzko, S., Pinato, D. J., Robey, R. C., Pria, A. D., Benson, P., Imami, N., & Bower, M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1304337 · Cited by 24
“otherwise untreatable cancers, most notably melanoma, renalcell carcinoma and non-small-cell lung carcinoma,(9-11) led to them being named “Breakthrough of the Year” by Science journal in 2013.(12) Kaposi’s sarcoma (KS) is a mesenchymal tumor caused by an infection by human herpesvirus 8 (HHV8), usually in the context…”
Background
Cblb -deficient T cells are less susceptible to PD-L1-mediated inhibition
Peer, S., Baier, G., & Gruber, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18360 · Cited by 26
Imagerie médicale computationnelle (radiomique) et potentiel en immuno-oncologie
Sun, R., Limkin, E. J., Dercle, L., Reuzé, S., Zacharaki, E. I., Chargari, C., Schernberg, A., Dirand, A.-S., Alexis, A., Nikos Paragios, A., et al. (2017) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2017.07.035 · Cited by 25
Peptide Super-Agonist Enhances T-Cell Responses to Melanoma
Galloway, S. A. E., Dolton, G. M., Attaf, M., Wall, A., Fuller, A., Rius, C., Bianchi, V., Theaker, S. M., Lloyd, A., Caillaud, M. E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00319 · Cited by 22
What does the future hold for immunotherapy in cancer?
Naidoo, J., Li, B. T., Schindler, K., & Page, D. B. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.05 · Cited by 22
“Cancer Immunotherapy—a therapeutic strategy of harnessing the immune system to recognize and clear cancer—was named by Science journal as ‘Breakthrough of the Year’ in 2013 (1).”
Background
The fuel and engine: The roles of reprogrammed metabolism in metastasis of primary liver cancer
Zhu, W., Lü, M., Wang, X., Xu, Z., Gao, C., & Qin, L. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.016 · Cited by 25
Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm
Xue, T., & Budde, L. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.01.006 · Cited by 23
High versus low dose irradiation for tumor immune reprogramming
de Olza, M. O., Bourhis, J., Irving, M. B., Coukos, G., & Herrera, F. G. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.08.001 · Cited by 24
Programmed albumin nanoparticles regulate immunosuppressive pivot to potentiate checkpoint blockade cancer immunotherapy
Feng, L., Yang, L., Li, L., et al. (2021) · Nano Research · doi:10.1007/s12274-021-3525-6 · Cited by 23
Disruption of Wnt/β-catenin Pathway Elevates the Sensitivity of Gastric Cancer Cells to PD-1 Antibody
Li, J., Zhang, H., Bei, S., Zhang, X., Li, H., Ye, L., & Feng, L. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210617163821 · Cited by 23
Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies
Sokolov, A. V., Dostdar, S. A., Attwood, M. M., Krasilnikova, A. A., Ilina, A. A., Nabieva, A. S., Lisitsyna, A. A., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000317 · Cited by 27
“Unfortunately, TCR T cells failed to demonstrate a more favorable safety profile, as one might expect, over CAR T cells in solid tumors, given that severe toxicities were reported from several clinical trials on different tumor types (D’Ippolito et al., 2019).”
Background
Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
Cejalvo, J. M., Falato, C., Villanueva, L., Tolosa, P., González, X., Pascal, M., Canes, J., Gavilá, J., Manso, L., Pascual, T., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102392 · Cited by 24
Identifying the optimal anticancer targets from the landscape of a cancer–immunity interaction network
Li, C. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp07767f · Cited by 23
Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
Fazel, M., Dufresne, A., Vanacker, H., Waïssi, W., Blay, J., & Brahmi, M. (2023) · Cancers · doi:10.3390/cancers15061643 · Cited by 24
SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
Zheng, X., Lin, J., Xiong, J., Guan, Y., Lan, B., Li, Y., Gao, X., Fei, Z., Chen, L., Chen, L., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10920-4 · Cited by 22
Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 30
Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
Huang, Y., Chen, Z., Shen, G., Fang, S., Zheng, J., Chi, Z., Zhang, Y., Zou, Y., Gan, Q., Liao, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2318815 · Cited by 23
Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu‐SCID model
Brady, J. L., Harrison, L. C., Goodman, D. J., Cowan, P. J., Hawthorne, W. J., O’Connell, P. J., Sutherland, R. M., & Lew, A. M. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.28 · Cited by 23
Profiling networks of distinct immune-cells in tumors
Clancy, T., & Hovig, E. J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1141-3 · Cited by 22
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy
Perna, F., & Sadelain, M. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.15 · Cited by 25
“This novel cell-based immunotherapy was highlighted, together with checkpoint blockade, as the basis for selecting cancer immunotherapy as the scientific breakthrough of the year in 2013 (3).”
Background
Immuno-Oncology: The Third Paradigm in Early Drug Development
Martín-Liberal, J., Hierro, C., de Olza, M. O., & Rodon, J. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0471-4 · Cited by 24
Helper T Cells and Cancer-Associated Inflammation: A New Direction for Immunotherapy?
Dong, C. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2017.0012 · Cited by 23
“Recent studies and practice on using checkpoint blockade or expanded or engineered cytotoxic T cells as immunotherapy against tumors have highlighted antitumor immunity as a valid therapy for cancer (Couzin-Frankel 2013).”
Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature
Kopalli, S. R., Kang, T., Lee, K., & Koppula, S. (2018) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892813666181029142812 · Cited by 23
TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma
Wu, P., Xiang, T., Wang, J., Lv, R., & Wu, G. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12993 · Cited by 23
Non-genetic Heterogeneity of Macrophages in Diseases—A Medical Perspective
Gessain, G., Blériot, C., & Ginhoux, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.613116 · Cited by 24
Harnessing Pyroptosis for Cancer Immunotherapy
Bourne, C. M., & Taabazuing, C. Y. (2024) · Cells · doi:10.3390/cells13040346 · Cited by 27
Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 23
Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells
Ostrand‐Rosenberg, S., Horn, L. A., & Álvarez, J. A. G. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1677-5 · Cited by 22
“Cancer immunotherapy was recognized by Science Magazine in 2013 as the “Breakthrough of the Year” [1], and This paper is a Focussed Research Review based on a presentation given at the Fourteenth International Conference on Progress in Vaccination against Cancer (PIVAC 14), held in Rome, Italy, 24th–26th September, 20…”
Influential
Harnessing the immune system for cancer therapy
Smith, E. L., Zamarin, D., & Lesokhin, A. M. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000128 · Cited by 22
“The journal Science named cancer immunotherapy as the ‘breakthrough of the year’ for 2013 [1] to acknowledge significant progress in adoptive cellular therapy and immune checkpoint modulation as cancer therapeutics.”
Background
Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer
Huang, Y., & Carbone, D. P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.003 · Cited by 22
Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study
Goto, K., Annan, D. A., Morita, T., Li, W., Muroyama, R., Matsubara, Y., Ito, S., Nakagawa, R., Tanoue, Y., Jinushi, M., et al. (2016) · Scientific Reports · doi:10.1038/srep38407 · Cited by 22
Evaluation of antitumor effect of oxygen nanobubble water on breast cancer‐bearing BALB/c mice
Mahjour, A., Khazaei, M., Nourmohammadi, E., Khoshdel‐Sarkarizi, H., Ebrahimzadeh‐Bideskan, A., Rahimi, H. R., & Afshar, A. S. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28821 · Cited by 22
Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy
Patel, K. J., Siraj, S., Smith, C., Nair, M. P., Vishwanatha, J. K., & Basha, R. M. (2019) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2019031417 · Cited by 22
Opportunities and Challenges for Antibodies against Intracellular Antigens
Yang, X., Xie, S., Yang, X., Jumbo, J. C. C., Hou, X., Tang, Z., Yao, H., Mo, F., Yin, S., Liu, A., et al. (2019) · Theranostics · doi:10.7150/thno.35486 · Cited by 22
The Superior Ability of Human BDCA3+ (CD141+) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells
Gu, F., Zhang, K., Ma, L., Liu, Y., Li, C., Hu, Y., Yang, Q., Liang, J., Zeng, Y., Wang, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01267 · Cited by 22
Immunostimulatory biomaterials to boost tumor immunogenicity
Shofolawe-Bakare, O. T., Stokes, L. D., Hossain, M., Smith, A. E., & Werfel, T. A. (2020) · Biomaterials Science · doi:10.1039/d0bm01183e · Cited by 24
Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE—an enhanced deconvolution method
Fernández, E. A., Mahmoud, Y. D., Veigas, F., Rocha, D., Miranda, M., Merlo, J. P., Balzarini, M., Luján, H. D., Rabinovich, G. A., & Girotti, M. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa317 · Cited by 23
Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
Tan, Z., Chiu, M. S., Yan, C. W., Man, K., & Chen, Z. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.010 · Cited by 22
Potential of Black Phosphorus in Immune‐Based Therapeutic Strategies
Dong, W., Hu, W., Liu, H., Zhou, C., Zhang, X., Wang, S., & Lin, H. (2022) · Bioinorganic Chemistry and Applications · doi:10.1155/2022/3790097 · Cited by 22
“Immunotherapy, which topped the list of 10 scientic breakthroughs in 2013 [1], is considered the fourth most common mainstream treatment mode of cancer following surgery, chemotherapy, and radiotherapy.”
Background
Advances in the Pharmacological Activities and Effects of Perilla Ketone and Isoegomaketone
Wang, R., Zhang, Q., Feng, C., Zhang, J., Qin, Y., & Meng, L. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8809792 · Cited by 22
De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity
Shin, M. K., Jang, B.-Y., Bu, K.-B., Lee, S., Han, D.-H., Oh, J. W., & Sung, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415594 · Cited by 22
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
Jiménez-Reinoso, A., Tirado, N., Martínez‐Moreno, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005333 · Cited by 22
Recent advances in hydrogels for preventing tumor recurrence
Qian, Q., Song, J., Chen, C., Pu, Q., Liu, X., & Wang, H. (2023) · Biomaterials Science · doi:10.1039/d3bm00003f · Cited by 24
Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy
Yang, M., Chen, Y., Zhu, L., You, L., Tong, H., Meng, H., Sheng, J., & Jin, J. (2024) · Biomolecules · doi:10.3390/biom14010083 · Cited by 25
“This can be achieved through a variety of mechanisms, including the suppression of immunosuppressive cells and the activation of effector immune cells [107].”
Background
Edaravone: A Novel Possible Drug for Cancer Treatment?
Duranti, E., Cordani, N., & Villa, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031633 · Cited by 25
TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis
He, G., Zheng, C., Huo, H.-P., et al. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.09.015 · Cited by 22
Probing protein flexibility reveals a mechanism for selective promiscuity
Pabon, N. A., & Camacho, C. J. (2017) · eLife · doi:10.7554/elife.22889 · Cited by 23
“Although two PD-1-targeting antibodies already exist on the market, there are no small-molecule PD-1 inhibitors in clinical trial, despite the enormous interest in this blockbuster immunotherapy target (Dömling and Holak, 2014; Couzin-Frankel, 2013; Zarganes-Tzitzikas et al., 2016).”
Background
4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms
Finiuk, N. S., Boіko, N. M., Klyuchivska, O., Коbylinska, L. I., Kril, I., Zimenkovsky, B. S., Lesyk, R., & Stoika, R. S. (2017) · Croatian Medical Journal · doi:10.3325/cmj.2017.58.129 · Cited by 22
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
Audenet, F., Farkas, A. M., Anastos, H., et al. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2359-7 · Cited by 22
“Systemic immune checkpoint blockade has recently changed the treatment landscape for advanced bladder cancer [5].”
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014
Appelbaum, F. R., Anasetti, C., Antin, J. H., Atkins, H. L., Davies, S. M., Devine, S. M., Giralt, S., Heslop, H. E., Laport, G. G., Lee, S. J., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.003 · Cited by 22
Mitochondrial Inhibition: a Treatment Strategy in Cancer?
Bueno, M. J., Ruiz-Sepulveda, J. L., & Quintela-Fandiño, M. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01033-x · Cited by 22
Gene expression and immune infiltration in melanoma patients with different mutation burden
Wang, L., Fu, C. S., Liu, R., Shi, L., Zhao, G., & Yan, Z. (2021) · BMC Cancer · doi:10.1186/s12885-021-08083-1 · Cited by 22
Identification and validation of an immune-related prognostic signature and key gene in papillary thyroid carcinoma
Qin, R., Li, C., Wang, X., Zhong, Z., & Sun, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02066-9 · Cited by 22
Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis
Zhu, H., Jia, Z., Trush, M. A., & Li, Y. R. (2016) · doi:10.20455/ros.2016.853 · Cited by 22
“Indeed, immunotherapy with antibody blockage of CTLA-4 (an inhibitor of T cell immunity) or PD-1 (a checkpoint protein on T cells) has recently emerged as a promising strategy for treating advanced melanoma in humans [20–22].”
Background
Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy
Singh, S. D., Singh, N., Baranwal, M., Sharma, S., Devi, S., & Kumar, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03826-2 · Cited by 24
Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review
Lim, M. Y., Hong, S., & Nam, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512683 · Cited by 25
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan
Li, L., Wu, J., Cao, W., Zhang, W., Wu, Q., Li, Y., Yang, Y., Shan, Z., Zheng, Z., Ge, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02219-6 · Cited by 23
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy
Xu, Z., Liu, S., Li, Y., Wu, Y., Tu, J., Chen, Q., & Sun, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.039 · Cited by 26
Immunotherapeutic options on the horizon in breast cancer treatment
van Rooijen, J. M., Stutvoet, T. S., Schröder, C. P., & de Vries, E. G. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.09.003 · Cited by 21
EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity
Peled, M., Dragovich, M. A., Adam, K. R., Strazza, M., Tocheva, A. S., Vega, I. E., & Mor, A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800839 · Cited by 19
A quantum biochemistry approach to investigate checkpoint inhibitor drugs for cancer
Tavares, A. B. M. L. A., Neto, J. X., Fulco, U. L., et al. (2019) · New Journal of Chemistry · doi:10.1039/c8nj05561k · Cited by 21
Cancer immunotherapy harnessing γδ T cells and programmed death‐1
Tanaka, Y. (2020) · Immunological Reviews · doi:10.1111/imr.12917 · Cited by 21
Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation
Liu, W., Jin, H., Chen, T., Zhang, G., Lai, S., & Liu, G. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.574759 · Cited by 21
“Cancer immunotherapy comprises various treatment approaches, including antitumor monoclonal antibodies, cancer vaccines, and antibodies that block immune inhibitory pathways (Mellman et al., 2011; Couzin-Frankel, 2013).”
Background
Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer
Haftcheshmeh, S. M., Zamani, P., Mashreghi, M., Nikpoor, A. R., Tavakkol‐Afshari, J., & Jaafari, M. R. (2020) · Biotechnology Progress · doi:10.1002/btpr.3095 · Cited by 21
PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models
Kim, D., Lee, S. S., Moon, H., Park, S. Y., & Lee, H. J. (2020) · Pharmaceuticals · doi:10.3390/ph14010006 · Cited by 21
The mechanisms of action of Plasmodium infection against cancer
Chen, X., Li, Q., Hu, W., et al. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00748-5 · Cited by 21
A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy
Syeda, M. Z., Hong, T., Zhang, M., Han, Y., Zhu, X., Ying, S., & Tang, L. (2022) · Nano Research · doi:10.1007/s12274-022-4598-6 · Cited by 22
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer
Sewnath, C. A. N., Behrens, L. M., & van Egmond, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2098675 · Cited by 22
Biomimetic Cancer Cell-Coated Albumin Nanoparticles for Enhanced Colloidal Stability and Homotypic Targeting of Breast Cancer Cells
Cao, Y., Yang, Y., Feng, S., & Wan, Y. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103698 · Cited by 24
Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy
Jia, Y., Wang, Y., Chard, L. S., Lemoine, N. R., Wang, P., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126969 · Cited by 22
Radiation meets immunotherapy – a perfect match in the era of combination therapy?
Soukup, K., & Wang, X. (2015) · International Journal of Radiation Biology · doi:10.3109/09553002.2014.995383 · Cited by 23
“With its nomination as Science ‘Breakthrough of the Year 2013’ (Couzin-Frankel 2013) and preclinical studies gradually translating into clinical data, the field of CIT has finally reached a state of acceptance among the established oncological domains.”
Background
STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?
Lemos, H. D. P., Huang, L., McGaha, T. L., & Mellor, A. L. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.995097 · Cited by 21
“In particular, reagents that target common regulatory pathways found in tumor microenvironments (‘checkpoint blockade’) have led to some remarkable responses in preclinical studies; prompting the editors of Science magazine to cite cancer immunotherapy as the scientific breakthrough of 2013 [55].”
TCR diversity – a universal cancer immunotherapy biomarker?
McNeel, D. G. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0175-4 · Cited by 21
“Dramatic treatment responses with T-cell checkpoint inhibitors for multiple tumor types, and CAR-T cell approaches for B cell malignancies, led the journal Science to declare that cancer immunotherapy was the scientific breakthrough of the year in 2013 [1].”
Background
Chimaeric antigen receptor T-cell therapy for tumour immunotherapy
Sha, H., Wang, D., Yan, D., Hu, Y., Yang, S., Liu, S.-W., & Feng, J. (2017) · Bioscience Reports · doi:10.1042/bsr20160332 · Cited by 21

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks